Innoviva — Third Quarter 2026 Earnings Summary

Innoviva reported third-quarter 2026 total revenue of $106.1 million, driven by a 45% year-over-year increase in U.S. net product sales to $43.3 million within its Innoviva Specialty Therapeutics segment. The company generated $58.1 million in stable royalty revenue from its partnership with Glaxo Group Limited, while repurchasing 1.2 million shares for $26.3 million under its ongoing buyback program. Despite strong operational growth, Innoviva recorded a net loss of $73.9 million for the quarter, primarily due to a $139.5 million decline in the fair value of its equity and long-term investments.